Skip to main content
. 2023 Mar 11;15(6):1369. doi: 10.3390/nu15061369

Table 2.

Associations between quality-of-life functions and MAG-EPA intervention, intention-to-treat analysis.

Variables Placebo MAG-EPA Difference between Group
Mean (SE) MD (95% CI) p-Value * Mean (SE) MD (95% CI) p-Value * MD (95% CI) p-Value **
EPIC-26      
Urinary Incontinence            
  Randomization 94.7 (2.0) 0.0    94.5 (1.9) 0.0         
  3 Months Post-RP 47.9 (3.4) −46.8 (−54.3; −39.4) <0.0001 36.8 (3.3) −57.6 (−65.1; −50.1) <0.0001 −9.8 (−19.2; −0.4) 0.04
  6 Months Post-RP 66.7 (3.6) −28.0 (−36.0; −20.1) <0.0001 58.6 (3.7) −35.8 (−43.9; −27.8) <0.0001 −6.6 (−16.6; 3.5) 0.20
  9 Months Post-RP 69.3 (3.5) −25.4 (−32.8; −18.1) <0.0001 67.0 (3.5) −27.4 (−35.0; −19.9) <0.0001 −0.5 (−10.0; 9.0) 0.92
  12 Months Post-RP 73.2 (3.5) −21.5 (−28.7; −14.3) <0.0001 66.5 (3.6) −27.9 (−35.4; −20.5) <0.0001 −3.7 (−13.4; 6.0) 0.45
Urinary irritation                        
  Randomization 85.6 (2.1) 0.0    83.1 (2.0) 0.0         
  3 Months Post-RP 78.5 (2.1) −7.1 (−11.9; −2.2) 0.005 79.1 (2.0) −4.1 (−8.9; 0.8) 0.10 1.6 (−3.9; 7.1) 0.57
  6 Months Post-RP 85.3 (1.8) −0.3 (0.1; 8.8) 0.90 87.8 (1.8) 4.7 (0.4; 8.9) 0.03 2.6 (−1.8; 7.0) 0.24
  9 Months Post-RP 86.9 (1.8) 1.4 (−2.3; 5.1) 0.47 87.3 (1.8) 4.1 (0.4; 7.8) 0.03 1.7 (−2.4; 5.8) 0.42
  12 Months Post-RP 86.6 (1.7) 1.0 (−3.0; 5.1) 0.62 88.8 (1.7) 5.6 (1.5; 9.6) 0.007 3.5 (−0.8; 7.8) 0.11
Sexual function                        
  Randomization 65.7 (3.7) 0.0    62.8 (3.6) 0.0         
  3 Months Post-RP 19.6 (2.8) −46.1 (−53.4; −38.9) <0.0001 17.7 (2.8) −45.1 (−52.3; −37.8) <0.0001 −1.8 (−9.0; 5.4) 0.62
  6 Months Post-RP 26.3 (3.3) −39.4 (−46.8; −31.9) <0.0001 26.2 (3.3) −36.6 (−44.1; −29.2) <0.0001 −0.4 (−8.6; 7.9) 0.93
  9 Months Post-RP 32.0 (3.5) −33.7 (−40.8; −26.6) <0.0001 30.5 (3.5) −32.3 (−39.5; −25.2) <0.0001 −1.8 (−10.4; 6.7) 0.67
  12 Months Post-RP 36.0 (3.8) −29.7 (−37.2; −22.3) <0.0001 31.5 (3.8) −31.3 (−38.8; −23.8) <0.0001 −4.5 (−14.0; 5.0) 0.35
Bowel function                        
  Randomization 92.8 (1.7) 0.0    90.2 (1.6) 0.0         
  3 Months Post-RP 91.3 (1.6) −1.5 (−5.2; 2.2) 0.42 89.7 (1.7) −0.5 (−4.2; 3.2) 0.77 −0.8 (−5.2; 3.7) 0.72
  6 Months Post-RP 93.0 (1.4) 0.2 (−2.8; 3.2) 0.90 91.4 (1.3) 1.2 (−1.8; 4.3) 0.43 −1.0 (−4.3; 2.3) 0.55
  9 Months Post-RP 93.0 (1.7) 0.2 (−3.4; 3.8) 0.93 90.8 (1.7) 0.6 (−3.2; 4.2) 0.76 −0.4 (−4.5; 3.7) 0.84
  12 Months Post-RP 95.2 (1.3) 2.4 (−0.5; 5.2) 0.11 94.0 (1.2) 3.8 (0.9; 6.7) 0.009 −0.6 (−3.4; 2.2) 0.69
Hormonal function                        
  Randomization 85.9 (2.0) 0.0    88.3 (1.9) 0.0         
  3 Months Post-RP 85.8 (1.9) −0.1 (−3.8; 3.6) 0.96 88.2 (1.8) −0.1 (−3.8; 3.7) 0.97 0.9 (−3.4; 5.3) 0.66
  6 Months Post-RP 88.1 (1.6) 2.2 (−1.3; 5.8) 0.21 88.2 (1.5) −0.1 (−3.6; 3.4) 0.96 −0.3 (−3.9; 3.4) 0.89
  9 Months Post-RP 87.5 (1.6) 1.6 (−1.7; 4.9) 0.33 89.4 (1.5) 1.2 (−2.2; 4.5) 0.49 1.4 (−2.2; 5.0) 0.43
  12 Months Post-RP 86.6 (1.7) 0.7 (−2.5; 4.0) 0.66 89.2 (1.7) 1.0 (−2.2; 4.2) 0.55 1.6 (−2.0; 5.3) 0.36
IPSS         
Voiding and storage Problem                        
  Randomization 9.0 (0.9) 0.0    8.8 (0.8) 0.0         
  3 Months Post-RP 11.2 (0.9) 2.2 (0.1; 4.3) 0.04 10.3 (0.9) 1.5 (−0.6; 3.6) 0.17 −0.9 (−3.2; 1.4) 0.43
  6 Months Post-RP 7.7 (0.7) −1.2 (−3.0; 0.5) 0.17 7.8 (0.7) −1.0 (−2.7; 0.8) 0.28 0.1 (−1.6; 1.8) 0.91
  9 Months Post-RP 7.3 (0.7) −1.7 (−3.3; 0.0) 0.05 6.5 (0.7) −2.3 (−4.0; −0.6) 0.007 −0.9 (−2.7; 0.8) 0.30
  12 Months Post-RP 6.9 (0.7) −2.1 (−3.8; −0.4) 0.02 5.9 (0.6) −2.9 (−4.6; −1.2) 0.0008 −1.1 (−2.8; 0.5) 0.17

Notes: MAG-EPA: monoacylglyceride-conjugated eicosapentaenoic acid; RP: radical prostatectomy. * p-value were obtained by mixed models adjusted for age. BMI and NCCN risk; ** p-value were obtained by mixed models adjusted for age, BMI, NCCN risk, and baseline score.